Navigation Links
Potential for Adult Stem Cells to Repair Hearts Damaged Investigated

Rush University Medical Center is one of the first medical centers in the country, and currently the only site in Illinois, participating in a novel clinical trial to// determine if a subject’s own stem cells can treat a form of severe coronary artery disease.

The Autologous Cellular Therapy CD34-Chronic Myocardial Ischemia (ACT34-CMI) Trial is the first human, Phase II adult stem cell therapy study in the U.S. designed to investigate the efficacy, tolerability, and safety of blood-derived selected CD34+ stem cells to improve symptoms and clinical outcomes in subjects with chronic myocardial ischemia (CMI), a severe form of coronary artery disease.

"What we’re hoping is that these stem cells will be able to stimulate the growth of new blood vessels to bring more blood and oxygen to the heart muscle, so that these patients will have a better quality of life and less chest pain," said Dr. Gary Schaer, director of the Rush Cardiac Catheterization Lab and study investigator.

Myocardial ischemia is a serious heart condition that involves narrowing of coronary arteries and results in limited blood flow to the heart. The disease affects hundreds of thousands of new people each year. A person who suffers from chronic myocardial ischemia continues to experience insufficient flow of oxygen-rich blood to the heart despite optimum medical intervention.

The study is a randomized, double-blind, placebo-controlled study that involves adult subjects with severe coronary artery disease who are currently on the maximum medical therapy and who are not suitable candidates for conventional procedures to improve blood flow to the heart such as angioplasty, stents, or coronary artery bypass surgery.

Rush is one of 15 to 20 research sites nationwide participating in the study, which is sponsored by the Cellular Therapies business unit of Baxter Healthcare Corporation. Baxter technology is used to select the subject’s own CD34+ stem cells th at are under investigation in this trial.

The baseline frequency and severity of anginal episodes are established as a first step for all study subjects. Next, all subjects receive a series of subcutaneous injections (needle shots, typically delivered under the skin in the arm, thigh or abdomen) of a commercially produced protein (granulocyte colony stimulating factor). The protein helps to release CD34+ stem cells (also known as endothelial progenitor cells) from a subject’s bone marrow into the bloodstream.

Then, investigators use a cell separation system, similar to the automated systems that are used with people who donate specific blood components such as platelets or red blood cells, to collect from the subject’s bloodstream, an enriched preparation of cells that contain CD34+ stem cells. When this process, known as apheresis, is complete, technologists further process the collected stem cells with Baxter’s ISOLEX 300i Magnetic Cell Selection System, currently approved for use with cancer patients, to select the subject’s CD34+ stem cells for use in this investigational therapy.

Schaer then uses a catheter-based, non-surgical system to map the patient’s heart three-dimensionally to identify the damaged areas into which the stem cells would be injected. "This targeted approach increases the treatment's effectiveness by delivering the stem cells exactly where they are needed." Schaer uses the Johnson & Johnson’s NOGA XP Cardiac Navigation System to identify Ischemic but viable regions of the heart as targets for cell delivery. The researchers then use a special investigational catheter that functions like a "global positioning system" to precisely deliver CD34+ cells, or placebo, into the areas of the heart that have been identified as having poor blood flow.

Subjects are randomly selected to receive either one of two dosing levels of CD34+ stem cells, or placebo. Rush researchers will conduct follow-up examinations for 12 months. Researchers are encouraged by reports that the therapy appeared to be well-tolerated and no serious adverse events directly related to the stem cell therapy in an earlier study. According to preliminary, anecdotal patient reports, 16 of the 24 total Phase I study subjects reported feeling better with reductions in chest pain and improved exercise capacity during the early stage of the trial.

Source-Bio-Bio Technolog
SRI
'"/>




Related medicine news :

1. Potential New Cancer Gene Identified
2. Lack of Smell And Its Potential Risks
3. New Blood Thinner Pill - First Potential Alternative to Warfarin in 50 years
4. The Potential Of Cadaver Transplantation Programme In India
5. Another Potential Of Stem Cells Discovered: Used For Growing Cartilage
6. Yoga Guru Ramdev Invited to Tap Ayurveda Potential by Jharkhand Govt
7. A Protein In Yoghurt Has The Potential To Fight E. coli
8. Gold Therapy- A Potential Treatment For Autoimmune Diseases
9. Whirlpool Bath Tubs Contain Potentially Lethal Bacterial Strains
10. Potential Benefits Of New Nanotechnology
11. Hormone Can Foretell Presence Of Potentially Fatal Pulmonary Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/7/2016)... , ... December 07, 2016 , ... Levels of a ... damage, according to a study appearing online in the journal Radiology. , Heart disease ... to increase significantly due to the rapidly aging population. Damage to both organs often ...
(Date:12/7/2016)... ... , ... They are musicians and librarians, fashion designers and fitness instructors, actors, ... England and around the nation. What do they have in common? All have been ... and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport in ...
(Date:12/7/2016)... Hollywood, Fl (PRWEB) , ... December 07, 2016 , ... When it came time to ... new heart. Just 40 minutes later, the Pediatric Heart Transplant team at Joe ... true making the Weston teen the hospital’s 30th heart transplant recipient. , “He was ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, ... to the US market its advanced highly customizable contact technology solutions. , ODU ... These advanced technologies are ideal for a wide range of applications that require ...
(Date:12/7/2016)... Arbor, MI (PRWEB) , ... December 07, 2016 ... ... insurance and financial consultation services from offices located in South Lyon, Dewitt, Williamston, ... to benefit a basketball coach who needs treatment for a brain tumor. , ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Boehringer Ingelheim today announced that the ... malignant pleural mesothelioma (MPM) met its primary endpoint ... the 17 th IASLC World Conference on ... showed nintedanib plus pemetrexed/cisplatin demonstrated a meaningful clinical ... significantly improved PFS (9.4 vs 5.7 months). Preliminary ...
(Date:12/7/2016)... Dec. 7,2016  Based on its recent ... Frost & Sullivan recognizes Nemaura Pharma Limited ... Award for Enabling Technology Leadership. Nemaura Pharma,s ... in traditional drug delivery technologies, especially in ... drug delivery technologies, Memspatch and Micropatch respectively, ...
(Date:12/7/2016)... DIEGO , Dec. 7, 2016  Organovo ... a three-dimensional biology company focused on delivering scientific ... today announced that Chairman and Chief Executive Officer ... at VirtualInvestorConferences.com on Wednesday, December 14, 2016 at ... investors who are not yet familiar with the ...
Breaking Medicine Technology: